Telix Pharmaceuticals Limited

Veterans are twice as likely to be diagnosed with prostate cancer than the general population. That’s why we are returning this season to the Military Makeover with Montel, a US TV show, to raise awareness and help make a difference in the lives of brave service members. Tune in this morning at 7:30 AM ET/PT as #TeamTelix joins the show, airing exclusively on LifetimeTV. Military Makeover with Montel

Telix has “Gone Grey” this May to raise awareness of the impact of brain tumours. During the month, Telix staff held events across our global offices to highlight the challenges faced by patients and the important work that is being done to overcome these. To learn more about our investigational theranostic brain cancer portfolio visit: telixpharma.com/brain

Telix is pleased to announce additional positive data from the ProstACT SELECT trial of TLX591, Telix’s lead investigational radio antibody-drug conjugate (rADC) therapy for prostate cancer. The study has reported median radiographic progression-free survival (rPFS) of 8.8 months in a heavily pre-treated population of patients with PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC). This encouraging potential efficacy signal builds on previously reported data from SELECT, which demonstrated a favourable safety profile and biodistribution. The results support development in an earlier mCRPC patient population, where TLX591 is being further evaluated in the Phase III ProstACT GLOBAL trial, now preparing to enrol patients at its first U.S. sites. We would like to thank all patients and investigators for their commitment to this study and the development of TLX591. Read more here: https://bit.ly/3VmPSEx

Did you know that Black and African American men are twice as likely to die from prostate cancer as white men? Socioeconomic factors, racial bias and gaps in care all contribute to this inequity and need to be addressed. Telix is committed to closing the gap in prostate cancer care by striving for equitable access to advanced imaging for all men regardless of race, socioeconomic status and location. Learn more about the great work Patient Organisations are doing to improve health equity ZERO Prostate Cancer, Prostate Cancer Foundation, Veterans Prostate Cancer Awareness, AnCan Foundation

Join Telix this week at the ASCO Annual Meeting in Chicago (IL), where Telix’s lead therapy studies in prostate and kidney cancer will be presented. Come and meet the team at booth #21148 to discuss Telix’s extensive therapeutic and diagnostic (‘theranostic’) radiopharmaceutical pipeline in urologic oncology, neuro-oncology, musculoskeletal oncology and bone marrow conditioning, along with opportunities for collaboration. More on our presence at ASCO including details of abstract presentations here: https://bit.ly/44YDkWW

Telix has today announced that it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX007-CDx, a new cold kit for the preparation of PSMA-PET imaging for prostate cancer. Despite the commercial availability of PSMA-PET imaging agents in the U.S, access is still severely limited for underserved patient demographics in many regions. This most notably impacts African Americans and Veterans, who already experience much higher incidence rates of prostate cancer, including late-stage presentation, than the general population. Subject to regulatory approval, TLX007-CDx will enable use of a PSMA imaging product with a considerably extended distribution profile compared to currently approved gallium-68 (68Ga) PSMA-PET imaging agents. Read more here: https://bit.ly/4bDFLRl

Telix is pleased to announce the successful completion of CUPID, a first-in-human Phase I study of TLX592, its investigational antibody-based targeted alpha therapy for prostate cancer. Initial results establish proof-of-concept for Telix’s proprietary RADmAb® engineered antibody platform, currently under pre-clinical evaluation for multiple cancer targets. Based on encouraging results, Telix expects to advance TLX592 into a therapeutic Phase I/II study with actinium-225 in H2 2024, subject to regulatory approval. To read more about the results click here: https://lnkd.in/gtCSw5tR

Thank you to the tireless sponsors of the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199), in particular Congressman Dr Neal Dunn (Florida-02), for advancing this vital legislation out of the House Energy and Commerce Subcommittee on Health to the full Committee for consideration for the first time. If passed, this legislation would ensure appropriate Medicare reimbursement for innovative diagnostic imaging drugs, ensuring equitable access for patients across the United States. Telix strongly supports the FIND Act, which aligns closely with our mission to deliver on the promise of nuclear medicine. Read more here: https://bit.ly/4arhTyP

Today, on International Clinical Trials Day, we recognise the patients, researchers and their teams involved in trials for their dedication to advancing medical science. Thank you for your support in improving outcomes, providing a beacon of hope to patients everywhere. You inspire #TeamTelix every day. To learn more about clinical trials at Telix, visit: https://bit.ly/3wsyhl2 #CTD2024

Thank you for joining Telix at the American Urological Association #AUA24 Annual Meeting in San Antonio, Texas. We were pleased to host two Product Theaters, delving into Telix’s innovative theranostic programs in urology. These sparked meaningful conversations about the future of kidney cancer detection and management and the role of PSMA imaging in the initial staging of prostate cancer. The Meeting also featured several Telix related oral presentations, updating urologists on advancements in 68Ga-PSMA-11 and developments in the ProstACT Global Phase III study of TLX591, Telix’s first-in-class investigational PSMA-targeting radio antibody-drug conjugate therapy for prostate cancer. TLX591 has not received a marketing authorization in any jurisdiction.